Effect of DNA methylation inhibitor on RASSF1A genes expression in non-small cell lung cancer cell line A549 and A549DDP

Cancer Cell International

Li Shijun¹  Xiao Xiaoguang¹  Wang Nan¹  Wang Qian¹  Duan Mengxi¹ 

[1] Department of Clinical Laboratory, The First Affiliated Hospital of Dalian Medical University, Dalian 116011, China

关键词: Resistance;    Non-small cell lung cancer;    5-Aza-2′-deoxycytidine;    DNA methylation;    RASSF1A;   

Others  :  792909
DOI  :  10.1186/1475-2867-13-91

 received in 2013-04-25, accepted in 2013-09-03,  发布年份 2013

【 摘 要 】

Background

Ras association domain family 1A gene (RASSFlA) is a candidate suppressor gene, Lack of RASSF1A expression was found in lung cancer. High DNA methylation at the promoter region is the main reason for inactivating RASSF1A transcription.

Methods

In this study, we examined RASSF1A’s methylation status and its mRNA expression level between non-small cell lung cancer cell line A549 and anti-Cisplatin cell strain A549DDP, Furthermore, methylation of A549DDP was reversed by treatment of 5-Aza-2′ - deoxycytidine (5-Aza-cdR),a DNA methyltransferase inhibitor.

Results

We found that RASSF1A’s methylation status and its mRNA expression were obvious differences between A549 and A549DDP. 5-Aza-CdR treatment remarkablly reduced cell vability of A549DDP. Moreover, 5-Aza-CdR treatment induced A549DDP cell apoptosis in a dose dependent manner with declining cell percentage in S and G2/M stage, and increasing proportion in G0/G1 stage. Cell motility was blocked in G0/G1 stage. All of A549DDP cells showed unmethylated expression, its high methylation status was reversed in a dose-dependent manner within a certain range.

Conclusions

The abnormal gene methylation status of RASSF1A is a molecular biomarker in lung cancer diagnosis, treatment and prognosis.

【 授权许可】

   
2013 Mengxi et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Jemal A, Siegel R, Xu J, Ward E: Cancer statistics, 2010. CA Cancer J Clin 2010, 60(5):277-300.
• [2]Jack RH, Davies EA, Møller H: Lung cancer incidence and survival in different ethnic groups in South East England. Br J Cancer 2011, 105(7):1049-1053.
• [3]Van′t Westeinde SC, van Klaveren RJ: Review screening and early detection of lung cancer. Cancer J 2011, 17(1):3-10.
• [4]Belani CP, Langer C: Review first-line chemotherapy for NSCLC: an overview of relevant trials. Lung Cancer 2002, 38(Suppl 4):13-19.
• [5]Jones PA, Baylin SB: Review The fundamental role of epigenetic events in cancer. Nat Rev Genet 2002, 3(6):415-428.
• [6]Dammann R, Li C, Yoon JH, Chin PL, Bates S, Pfeifer GP: Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3. Nat Genet 2000, 25(3):315-319.
• [7]Amaar YG, Minera MG, et al.: Ras association domain family 1C protein stimμlates human lung cancer cell proliferation. Am J Physiol Lung Cell Mol Physiol 2006, 291(6):1185-1190.
• [8]Kim DH, Kim JS, Ji YI, Shim YM, Kim H, Han J, Park J: Hypermethylation of RASSF1A promoter is associated with the age at starting smoking and a poor prognosis in primary non-small cell lung cancer. Cancer Res 2003, 63(13):3743-3746.
• [9]Grote HJ: Aberrant promoter methylation as biomarker for molecular cytological diagnosis of lung cancer. Verh Dtsch Ges Pathol 2006, 90:216-226.
• [10]Liloglou T, Maloney P, Xinarianos G, Hulbert M, Walshaw MJ, Gosney JR, Turnbull L, Field JK: Cancer-specific genomic instability in bronchial lavage: a molecular tool for lung cancer detection. Cancer Res 2001, 61(4):1624-1628.
• [11]de Fraipont F, Moro-Sibilot D, Michelland S, Brambilla E, Brambilla C, Favrot MC: Promoter methylation of genes in bronchial lavages: a marker for early diagnosis of primary and relaps ing non-small cell lung cancer? Lung Cancer 2005, 50(2):199-209.
• [12]Schneider KU, Dietrich D, Fleischhacker M, Leschber G, Merk J, Schäper F, Stapert HR, Vossenaar ER, Weickmann S, Liebenberg V, Kneip C, Seegebarth A, Erdogan F, Rappold G, Schmidt B: Correlation of SHOX2 gene amplification and DNA methylation in lung cancer tumors. BMC Cancer 2011, 11:102. BioMed Central Full Text
• [13]Yang AS, Doshi KD, Choi SW, Mason JB, Mannari RK, Gharybian V, Luna R, Rashid A, Shen L, Estecio MR, Kantarjian HM, Garcia-Manero G, Issa JP: DNA methylation changes after 5-aza-2′-deoxycytidine therapy in patients with leukemia. Cancer Res 2006, 66(10):5495-5503.
• [14]Aoyama Y, Avruch J, Zhang XF: Nore1 inhibits tumor cell growth independent of Ras or the MST1/2 kinases. Oncogene 2004, 23(19):3426-3433.
• [15]Avruch J, Praskova M, Ortiz-Vega S, Liu M, Zhang XF: Nore1 and RASSF1 regulation of cell proliferation and of the MST1/2 kinases. Methods Enzymol 2006, 407:290-310.
• [16]Vos MD, Martinez A, Elam C, Dallol A, Taylor BJ, Latif F, Clark GJ: A role for the RASSF1A tumor suppressor in the regulation of tubulin polymerization and genomic stability. Cancer Res 2004, 64(12):4244-4250.
• [17]Pfeifer GP, Dammann R: Review methylation of the tumor suppressor gene RASSF1A in human tumors. Biochemistry (Mosc) 2005, 70(5):576-583.
• [18]Dammaim R, Sehaqdarsurenqin U, Liu L, et al.: Frequent RASSF1A promoter hypermethylation and K- ras mutations in panereatic carcinoma. Oneogene 2003, 22(24):3806.
• [19]Dawson MA, Kouzarides T: Review cancer epigenetics: from mechanism to therapy. Cell 2012, 150(1):12-27.
• [20]List AF, Vardiman J, Issa JP, DeWitte TM: Review myelodysplastic syndromes. Hematol Am Soc Hematol Educ Program 2004, 297-317.
• [21]Griffiths EA, Gore SD: Review epigenetic therapies in MDS and AML. Adv Exp Med Biol 2013, 754:253-283.
• [22]Tsai HC, Li H, Van Neste L, Cai Y, Robert C, Rassool FV, Shin JJ, Harbom KM, Beaty R, Pappou E, Harris J, Yen RW, Ahuja N, Brock MV, Stearns V, Feller-Kopman D, Yarmus LB, Lin YC, Welm AL, Issa JP, Minn I, Matsui W, Jang YY, Sharkis SJ, Baylin SB, Zahnow CA: Transient low doses of DNA-demethylating agents exert durable antitumor effects on hematological and epithelial tumor cells. Cancer Cell 2012, 21(3):430-446.